Survey Results Show HIT Adoption Supporting Patient Engagement
To fully understand the challenges and best practices for HIT adoption in ambulatory care settings, NextGen Healthcare commissioned Xtelligent Healthcare Media to conduct a survey of leaders at these healthcare organizations. The survey is one of a quarterly series to monitor HIT adoption and key trends in ambulatory facilities. This quarter's report emphasized patient engagement solutions to understand the technology's relationship with overall HIT strategies.
Explore moreNextGen® Advisors Podcast – Reflections on a Pandemic Milestone
The NextGen Advisors reflect on this milestone and the impact that vaccines have had on the course of the pandemic. The conversation sheds light on the underlying reasons for vaccine hesitancy and the special consideration for pediatric vaccines.
Explore moreAdvances in Technology Support a New Outlook in Eye Care
The only constant is change. This is as true in ophthalmic care as in any other field. Today, changes in technology have implications inside the exam room and beyond. What do these changes mean for the future of your practice?
Explore moreNextGen Advisors Podcast: Patient Adherence in the Era of COVID-19
Lack of adherence to a treatment regimen is estimated to cause approximately 125,000 annual deaths and cost the U.S. healthcare system between $100-289 billion per year. In this episode of the NextGen Advisors™ podcast, we explore the many factors associated with non-adherence as well as strategies providers may consider to address this challenge.
Explore moreCMS Releases Proposed 2022 Medicare Physician Payment Policies
On July 13, the Centers for Medicare & Medicaid Services (CMS) released its annual rule proposing updates to its payment system for physicians in Medicare. NextGen Advisor Chris Emper reviews some of the key elements and proposals.
Explore moreNextGen Advisors Podcast: FDA Approves Alzheimer’s Treatment, Controversy Ensues
Alzheimer’s disease affects 6.2 million Americans each year so the recent approval by the FDA of Biogen’s drug Aduhelm was met with hope by many patients and their advocates. The approval process used by the FDA, the efficacy data compiled to date, and the expected annual cost of the drug have created a swirl of controversy around the decision. In this <episode> of the NextGen Advisors podcast, Graham Brown and Dr. Betty Rabinowitz discuss the drug’s approval and the concerns, hopes and implications it has raised.
Explore more
The financial and clinical challenges you face now are evolving rapidly. Here are resources, solutions, and ideas we think will help.
Read Now